Market research
ALNEV.PA Neovacs S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14
- P/E ratio
- Not available
- Analyst target
- 1.13
- Dividend yield
- Not available
- Beta
- -1252.22
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR00140077X1
- Market cap
- 14
- P/E ratio
- Not available
- Analyst target
- 1.13
- Dividend yield
- Not available
- Beta
- -1252.22
About
About Neovacs S.A
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALNEV.PA discussion.
5 years, 5 months ago
Neovacs S.A is currently in a long term downtrend where the price is trading 81.4% below its 200 day moving average.
From a valuation standpoint, the stock is 914.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2774.2.
Based on the above factors, Neovacs S.A gets an overall score of 0/5.